nach oben

Erschienen in:

21.01.2022 | Heart Failure

Doxorubicin-Induced Cardiotoxicity: An Overview on Pre-clinical Therapeutic Approaches

verfasst von: Mohammad Sheibani, Yaser Azizi, Maryam Shayan, Sadaf Nezamoleslami, Faezeh Eslami, Mohammad Hadi Farjoo, Ahmad Reza Dehpour

Erschienen in: Cardiovascular Toxicology | Ausgabe 4/2022

Einloggen, um Zugang zu erhalten

Abstract

Doxorubicin is an effective chemotherapeutic agent prescribed to treat solid tumors (e.g., ovary, breast, and gastrointestinal cancers). This anti-cancer drug has various side effects, such as allergic reactions, cardiac damage, hair loss, bone marrow suppression, vomiting, and bladder irritation. The most dangerous side effect of doxorubicin is cardiomyopathy, leading to congestive heart failure. The exact mechanisms of doxorubicin-induced cardiotoxicity remain incompletely understood. Alteration in myocardial structure and functional cardiac disorders is provoked by doxorubicin administration; subsequently, cardiomyopathy and congestive heart failure can occur. Congestive heart failure due to doxorubicin is associated with mortality and morbidity. Probably, doxorubicin-induced cardiotoxicity starts from myocardial cell injury and is followed by left ventricular dysfunction. Many factors and multiple pathways are responsible for the creation of doxorubicin-induced cardiotoxicity. Inflammatory cytokines, oxidative stress pathways, mitochondrial damage, intracellular Ca²⁺ overload, iron-free radical production, DNA, and myocyte membrane injuries have critical roles in the pathophysiology of doxorubicin-induced cardiotoxicity. Unfortunately, there are currently a few medications for the treatment of doxorubicin-induced cardiotoxicity in clinical settings. Extensive basic and clinical researches have been carried out to discover preventive treatments. This review briefly discusses the basic and experimental approaches for treating or preventing doxorubicin-mediated cardiotoxicity based on its pathophysiological mechanisms.

Najafi, M., Shayesteh, M. R. H., Mortezaee, K., Farhood, B., & Haghi-Aminjan, H. (2020). The role of melatonin on doxorubicin-induced cardiotoxicity: A systematic review. Life Sciences, 241, 117173.PubMed

Sung, H., Ferlay, J., Siegel, R. L., Laversanne, M., Soerjomataram, I., Jemal, A., & Bray, F. (2021). Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA: A Cancer Journal for Clinicians, 71, 209–249.

Young, R. C., Ozols, R. F., & Myers, C. E. (1981). The anthracycline antineoplastic drugs. New England Journal of Medicine, 305, 139–153.

Narkiewicz, K., Ratcliffe, L. E., Hart, E. C., Briant, L. J., Chrostowska, M., Wolf, J., Szyndler, A., Hering, D., Abdala, A. P., & Manghat, N. (2016). Unilateral carotid body resection in resistant hypertension: A safety and feasibility trial. JACC: Basic to Translational Science, 1, 313–324.PubMedPubMedCentral

Hardaway, B. W. (2019). Adriamycin-associated cardiomyopathy: Where are we now? Updates in pathophysiology, dose recommendations, prognosis, and outcomes. Current Opinion in Cardiology, 34, 289–295.PubMed

Arcamone, F., Cassinelli, G., Fantini, G., Grein, A., Orezzi, P., Pol, C., & Spalla, C. (1969). Adriamycin, 14-hydroxydaimomycin, a new antitumor antibiotic from S. Peucetius var. caesius. Biotechnology and Bioengineering, 11, 1101–1110.PubMed

Kalyanaraman, B. (2020). Teaching the basics of the mechanism of doxorubicin-induced cardiotoxicity: Have we been barking up the wrong tree? Redox Biology, 29, 101394.PubMed

Yu, J., Wang, C., Kong, Q., Wu, X., Lu, J.-J., & Chen, X. (2018). Recent progress in doxorubicin-induced cardiotoxicity and protective potential of natural products. Phytomedicine, 40, 125–139.PubMed

Wenningmann, N., Knapp, M., Ande, A., Vaidya, T. R., & Ait-Oudhia, S. (2019). Insights into doxorubicin-induced cardiotoxicity: Molecular mechanisms, preventive strategies, and early monitoring. Molecular Pharmacology, 96, 219–232.PubMed

10.

Speth, P. A., van Hoesel, Q. G., & Haanen, C. (1988). Clinical pharmacokinetics of doxorubicin. Clinical Pharmacokinetics, 15, 15–31. https://doi.org/10.2165/00003088-198815010-00002CrossRefPubMed

11.

Von Hoff, D. D., Layard, M. W., Basa, P., Davis, H. L., Jr., Von Hoff, A. L., Rozencweig, M., & Muggia, F. M. (1979). Risk factors for doxorubicin-induced congestive heart failure. Annals of Internal Medicine, 91, 710–717. https://doi.org/10.7326/0003-4819-91-5-710CrossRef

12.

Steinherz, L. J., Steinherz, P. G., Tan, C. T. C., Heller, G., & Murphy, M. L. (1991). Cardiac toxicity 4 to 20 years after completing anthracycline therapy. JAMA, 266, 1672–1677. https://doi.org/10.1001/jama.1991.03470120074036CrossRefPubMed

13.

Ganz, P. A., Hussey, M. A., Moinpour, C. M., Unger, J. M., Hutchins, L. F., Dakhil, S. R., Giguere, J. K., Goodwin, J. W., Martino, S., & Albain, K. S. (2008). Late cardiac effects of adjuvant chemotherapy in breast cancer survivors treated on Southwest Oncology Group protocol s8897. Journal of Clinical Oncology, 26, 1223–1230. https://doi.org/10.1200/jco.2007.11.8877CrossRefPubMed

14.

Avagimyan, A., Mkrtchyan, L., Abrahomovich, O., Sheibani, M., Guevorkyan, A., Sarrafzadegan, N., Kozhukhov, S., Agati, L., Astengiano, R., Zaritska, V., & Jndoyan, Z. (2021). AC-mode of chemotherapy as a trigger of cardiac syndrome X: A case study. Current Problems in Cardiology. https://doi.org/10.1016/j.cpcardiol.2021.100994CrossRefPubMed

15.

Stark, C., Taimen, P., Savunen, T., & Koskenvuo, J. (2018). Pegylated and liposomal doxorubicin is associated with high mortality and causes limited cardiotoxicity in mice. BMC Research Notes, 11, 148. https://doi.org/10.1186/s13104-018-3260-6CrossRefPubMedPubMedCentral

16.

Boucek, R. J., Kunkel, E. M., Graham, T. P., Brenner, D., & Olson, R. D. (1987). Doxorubicinol, the metabolite of doxorubucin, is more cardiotoxic than doxorubicin. Pediatric Research, 21, 187–187. https://doi.org/10.1203/00006450-198704010-00127CrossRef

17.

Olson, R. D., Mushlin, P. S., Brenner, D. E., Fleischer, S., Cusack, B. J., Chang, B. K., & Boucek, R. J., Jr. (1988). Doxorubicin cardiotoxicity may be caused by its metabolite, doxorubicinol. Proceedings of the National Academy of Sciences of the United States of America, 85, 3585–3589. https://doi.org/10.1073/pnas.85.10.3585CrossRefPubMedPubMedCentral

18.

Lehenbauer Ludke, A. R., Al-Shudiefat, A.A.-R.S., Dhingra, S., Jassal, D. S., & Singal, P. K. (2009). A concise description of cardioprotective strategies in doxorubicin-induced cardiotoxicity. Canadian Journal of Physiology and Pharmacology, 87, 756–763.

19.

Pecoraro, M., Del Pizzo, M., Marzocco, S., Sorrentino, R., Ciccarelli, M., Iaccarino, G., Pinto, A., & Popolo, A. (2016). Inflammatory mediators in a short-time mouse model of doxorubicin-induced cardiotoxicity. Toxicology and applied pharmacology, 293, 44–52.PubMed

20.

Osataphan, N., Phrommintikul, A., Chattipakorn, S. C., & Chattipakorn, N. (2020). Effects of doxorubicin-induced cardiotoxicity on cardiac mitochondrial dynamics and mitochondrial function: Insights for future interventions. Journal of Cellular and Molecular Medicine, 24, 6534–6557.PubMedPubMedCentral

21.

Singal, P., Li, T., Kumar, D., Danelisen, I., & Iliskovic, N. (2000). Adriamycin-induced heart failure: Mechanisms and modulation. Molecular and Cellular Biochemistry, 207, 77–86.PubMed

22.

Minotti, G., Menna, P., Salvatorelli, E., Cairo, G., & Gianni, L. (2004). Anthracyclines: Molecular advances and pharmacologic developments in antitumor activity and cardiotoxicity. Pharmacological Reviews, 56, 185–229.PubMed

23.

Tokarska-Schlattner, M., Zaugg, M., Zuppinger, C., Wallimann, T., & Schlattner, U. (2006). New insights into doxorubicin-induced cardiotoxicity: The critical role of cellular energetics. Journal of Molecular and Cellular Cardiology, 41, 389–405.PubMed

24.

Aldieri, E., Bergandi, L., Riganti, C., Costamagna, C., Bosia, A., & Ghigo, D. (2002). Doxorubicin induces an increase of nitric oxide synthesis in rat cardiac cells that is inhibited by iron supplementation. Toxicology and Applied Pharmacology, 185, 85–90.PubMed

25.

Bahadır, A., Kurucu, N., Kadıoğlu, M., & Yenilme, E. (2014). The role of nitric oxide in Doxorubicin-induced cardiotoxicity: Experimental study. Turkish Journal of Hematology, 31, 68.PubMedPubMedCentral

26.

Nozaki, N., Shishido, T., Takeishi, Y., & Kubota, I. (2004). Modulation of doxorubicin-induced cardiac dysfunction in toll-like receptor-2-knockout mice. Circulation, 110, 2869–2874.PubMed

27.

Riad, A., Bien, S., Gratz, M., Escher, F., Heimesaat, M. M., Bereswill, S., Krieg, T., Felix, S. B., Schultheiss, H. P., & Kroemer, H. K. (2008). Toll-like receptor-4 deficiency attenuates doxorubicin-induced cardiomyopathy in mice. European Journal of Heart Failure, 10, 233–243.PubMed

28.

Hu, C., Zhang, X., Zhang, N., Wei, W. Y., Li, L. L., Ma, Z. G., & Tang, Q. Z. (2020). Osteocrin attenuates inflammation, oxidative stress, apoptosis, and cardiac dysfunction in doxorubicin-induced cardiotoxicity. Clinical and Translational Medicine, 10, e124.PubMedPubMedCentral

29.

Pecoraro, M., Sorrentino, R., Franceschelli, S., Del Pizzo, M., Pinto, A., & Popolo, A. (2015). Doxorubicin-mediated cardiotoxicity: Role of mitochondrial connexin 43. Cardiovascular Toxicology, 15, 366–376.PubMed

30.

Lyu, Y. L., Kerrigan, J. E., Lin, C.-P., Azarova, A. M., Tsai, Y.-C., Ban, Y., & Liu, L. F. (2007). Topoisomerase IIβ–mediated DNA double-strand breaks: Implications in doxorubicin cardiotoxicity and prevention by dexrazoxane. Cancer Research, 67, 8839–8846.PubMed

31.

Horie, T., Ono, K., Nishi, H., Nagao, K., Kinoshita, M., Watanabe, S., Kuwabara, Y., Nakashima, Y., Takanabe-Mori, R., & Nishi, E. (2010). Acute doxorubicin cardiotoxicity is associated with miR-146a-induced inhibition of the neuregulin-ErbB pathway. Cardiovascular Research, 87, 656–664.PubMedPubMedCentral

32.

Rohrbach, S., Muller-Werdan, U., Werdan, K., Koch, S., Gellerich, N. F., & Holtz, J. (2005). Apoptosis-modulating interaction of the neuregulin/erbB pathway with antracyclines in regulating Bcl-xS and Bcl-xL in cardiomyocytes. Journal of Molecular and Cellular Cardiology, 38, 485–493.PubMed

33.

Renu, K., Abilash, V., & Arunachalam, S. (2018). Molecular mechanism of doxorubicin-induced cardiomyopathy–An update. European Journal of Pharmacology, 818, 241–253.PubMed

34.

Lebrecht, D., Setzer, B., Ketelsen, U.-P., Haberstroh, J. R., & Walker, U. A. (2003). Time-dependent and tissue-specific accumulation of mtDNA and respiratory chain defects in chronic doxorubicin cardiomyopathy. Circulation, 108, 2423–2429.PubMed

35.

Lebrecht, D., Geist, A., Ketelsen, U. P., Haberstroh, J., Setzer, B., & Walker, U. (2007). Dexrazoxane prevents doxorubicin-induced long-term cardiotoxicity and protects myocardial mitochondria from genetic and functional lesions in rats. British Journal of Pharmacology, 151, 771–778.PubMedPubMedCentral

36.

Montaigne, D., Marechal, X., Baccouch, R., Modine, T., Preau, S., Zannis, K., Marchetti, P., Lancel, S., & Neviere, R. (2010). Stabilization of mitochondrial membrane potential prevents doxorubicin-induced cardiotoxicity in isolated rat heart. Toxicology and Applied Pharmacology, 244, 300–307.PubMed

37.

Danz, E. D. B., Skramsted, J., Henry, N., Bennett, J. A., & Keller, R. S. (2009). Resveratrol prevents doxorubicin cardiotoxicity through mitochondrial stabilization and the Sirt1 pathway. Free Radical Biology and Medicine, 46, 1589–1597.PubMed

38.

Liu, Y., Asnani, A., Zou, L., Bentley, V. L., Yu, M., Wang, Y., Dellaire, G., Sarkar, K. S., Dai, M., Chen, H. H., Sosnovik, D. E., Shin, J. T., Haber, D. A., Berman, J. N., Chao, W., & Peterson, R. T. (2014). Visnagin protects against doxorubicin-induced cardiomyopathy through modulation of mitochondrial malate dehydrogenase. Science Translational Medicine, 6, 266ra170. https://doi.org/10.1126/scitranslmed.3010189CrossRefPubMedPubMedCentral

39.

Fisher, P. W., Salloum, F., Das, A., Hyder, H., & Kukreja, R. C. (2005). Phosphodiesterase-5 inhibition with sildenafil attenuates cardiomyocyte apoptosis and left ventricular dysfunction in a chronic model of doxorubicin cardiotoxicity. Circulation, 111, 1601–1610. https://doi.org/10.1161/01.cir.0000160359.49478.c2CrossRefPubMed

40.

Beak, J., Huang, W., Parker, J. S., Hicks, S. T., Patterson, C., Simpson, P. C., Ma, A., Jin, J., & Jensen, B. C. (2017). An oral selective alpha-1A adrenergic receptor agonist prevents doxorubicin cardiotoxicity. JACC. Basic to translational science, 2, 39–53. https://doi.org/10.1016/j.jacbts.2016.10.006CrossRefPubMedPubMedCentral

41.

Yourtee, D. M., Elkins, L. L., Nalvarte, E. L., & Smith, R. E. (1992). Amplification of doxorubicin mutagenicity by cupric ion. Toxicology and Applied Pharmacology, 116, 57–65.PubMed

42.

Colombo, R., Dalle Donne, I., & Milzani, A. (1990). Metal ions modulate the effect of doxorubicin on actin assembly. Cancer Biochemistry Biophysics, 11, 217–226.PubMed

43.

Shi, Y., Moon, M., Dawood, S., McManus, B., & Liu, P. (2011). Mechanisms and management of doxorubicin cardiotoxicity. Herz, 36, 296–305.PubMed

44.

Panjrath, G. S., Patel, V., Valdiviezo, C. I., Narula, N., Narula, J., & Jain, D. (2007). Potentiation of doxorubicin cardiotoxicity by iron loading in a rodent model. Journal of the American College of Cardiology, 49, 2457–2464.PubMed

45.

Al-Shabanah, O. A., Aleisa, A. M., Hafez, M. M., Al-Rejaie, S. S., Al-Yahya, A. A., Bakheet, S. A., Al-Harbi, M. M., & Sayed-Ahmed, M. M. (2012). Desferrioxamine attenuates doxorubicin-induced acute cardiotoxicity through TFG-/Smad p53 pathway in rat model. Oxidative Medicine and Cellular Longevity. https://doi.org/10.1155/2012/619185CrossRefPubMedPubMedCentral

46.

Al-Harbi, M., Al-Gharably, N. M., Al-Shabanah, O. A., Al-Bekairi, A. M., Osman, A. M. M., & Tawfik, H. N. (1992). Prevention of doxorubicin-induced myocardial and haematological toxicities in rats by the iron chelator desferrioxamine. Cancer Chemotherapy and Pharmacology, 31, 200–204.PubMed

47.

Ammar, E.-S.M., Said, S. A., Suddek, G. M., & El-Damarawy, S. L. (2011). Amelioration of doxorubicin-induced cardiotoxicity by deferiprone in rats. Canadian Journal of Physiology and Pharmacology, 89, 269–276.

48.

van Acker, S. A., van Balen, G. P., van den Berg, D. J., Bast, A., & van der Vijgh, W. J. (1998). Influence of iron chelation on the antioxidant activity of flavonoids. Biochemical Pharmacology, 56, 935–943.PubMed

49.

Van Acker, S. A., Tromp, M. N., Griffioen, D. H., Van Bennekom, W. P., Van Der Vijgh, W. J., & Bast, A. (1996). Structural aspects of antioxidant activity of flavonoids. Free Radical Biology and Medicine, 20, 331–342.PubMed

50.

Bast, A., Haenen, G. R., Bruynzeel, A. M., & Van der Vijgh, W. J. (2007). Protection by flavonoids against anthracycline cardiotoxicity: From chemistry to clinical trials. Cardiovascular Toxicology, 7, 154–159.PubMed

51.

Willems, A. M., Bruynzeel, A. M., Kedde, M. A., Van Groeningen, C. J., Bast, A., & Van Der Vijgh, W. J. (2006). A phase I study of monohydroxyethylrutoside in healthy volunteers. Cancer Chemotherapy and Pharmacology, 57, 678–684.PubMed

52.

Bast, A., Kaiserová, H., Den Hartog, G., Haenen, G., & Van Der Vijgh, W. (2007). Protectors against doxorubicin-induced cardiotoxicity: Flavonoids. Cell Biology and Toxicology, 23, 39–47.PubMed

53.

Ehrke, M. J., Ryoyama, K., & Cohen, S. A. (1984). Cellular basis for adriamycin-induced augmentation of cell-mediated cytotoxicity in culture. Cancer Research, 44, 2497–2504.PubMed

54.

Maccubbin, D. L., Wing, K. R., Mace, K. F., Ho, R. L., Ehrke, M. J., & Mihich, E. (1992). Adriamycin-induced modulation of host defenses in tumor-bearing mice. Cancer Research, 52, 3572–3576.PubMed

55.

Nagai, K., Fukuno, S., Oda, A., & Konishi, H. (2016). Protective effects of taurine on doxorubicin-induced acute hepatotoxicity through suppression of oxidative stress and apoptotic responses. Anti-cancer Drugs, 27, 17–23.PubMed

56.

Wang, S., Kotamraju, S., Konorev, E., Kalivendi, S., Joseph, J., & Kalyanaraman, B. (2002). Activation of nuclear factor-κB during doxorubicin-induced apoptosis in endothelial cells and myocytes is pro-apoptotic: The role of hydrogen peroxide. Biochemical Journal, 367, 729–740.PubMedCentral

57.

Sheibani, M., Nezamoleslami, S., Faghir-Ghanesefat, H., Hossein Emami, A., & Dehpour, A. R. (2020). Cardioprotective effects of dapsone against doxorubicin-induced cardiotoxicity in rats. Cancer Chemotherapy and Pharmacology, 85, 563–571.PubMed

58.

Sun, Z., Yan, B., Yu, W. Y., Yao, X., Ma, X., Sheng, G., & Ma, Q. (2016). Vitexin attenuates acute doxorubicin cardiotoxicity in rats via the suppression of oxidative stress, inflammation and apoptosis and the activation of FOXO3a. Experimental and Therapeutic Medicine, 12, 1879–1884.PubMedPubMedCentral

59.

Shaker, R. A., Abboud, S. H., Assad, H. C., & Hadi, N. (2018). Enoxaparin attenuates doxorubicin induced cardiotoxicity in rats via interfering with oxidative stress, inflammation and apoptosis. BMC Pharmacology and Toxicology, 19, 1–10.

60.

Inchiosa, M. A., Jr., & Smith, C. M. (1990). Effects of ibuprofen on doxorubicin toxicity. Research Communications in Chemical Pathology and Pharmacology, 67, 63–78.PubMed

61.

Guo, R., Wu, K., Chen, J., Mo, L., Hua, X., Zheng, D., Chen, P., Chen, G., Xu, W., & Feng, J. (2013). Exogenous hydrogen sulfide protects against doxorubicin-induced inflammation and cytotoxicity by inhibiting p38MAPK/NFκB pathway in H9c2 cardiac cells. Cellular Physiology and Biochemistry, 32, 1668–1680.PubMed

62.

Yarmohammadi, F., Rezaee, R., & Karimi, G. (2021). Natural compounds against doxorubicin-induced cardiotoxicity: A review on the involvement of Nrf2/ARE signaling pathway. Phytotherapy Research, 35, 1163–1175.PubMed

63.

Xiong, C., Wu, Y. Z., Zhang, Y., Wu, Z. X., Chen, X. Y., Jiang, P., Guo, H. C., Xie, K. R., Wang, K. X., & Su, S. W. (2018). Protective effect of berberine on acute cardiomyopathy associated with doxorubicin treatment. Oncology Letters, 15, 5721–5729.PubMedPubMedCentral

64.

Asensio-López, M. C., Soler, F., Pascual-Figal, D., Fernández-Belda, F., & Lax, A. (2017). Doxorubicin-induced oxidative stress: The protective effect of nicorandil on HL-1 cardiomyocytes. PLoS ONE, 12, e0172803.PubMedPubMedCentral

65.

Morgan, M. J., & Liu, Z. G. (2011). Crosstalk of reactive oxygen species and NF-κB signaling. Cell Research, 21, 103–115. https://doi.org/10.1038/cr.2010.178CrossRefPubMed

66.

Zhao, Y., Miriyala, S., Miao, L., Mitov, M., Schnell, D., Dhar, S. K., Cai, J., Klein, J. B., Sultana, R., Butterfield, D. A., Vore, M., Batinic-Haberle, I., Bondada, S., & St Clair, D. K. (2014). Redox proteomic identification of HNE-bound mitochondrial proteins in cardiac tissues reveals a systemic effect on energy metabolism after doxorubicin treatment. Free Radical Biology & Medicine, 72, 55–65. https://doi.org/10.1016/j.freeradbiomed.2014.03.001CrossRef

67.

Guo, C., Sun, L., Chen, X., & Zhang, D. (2013). Oxidative stress, mitochondrial damage and neurodegenerative diseases. Neural Regeneration Research, 8, 2003–2014. https://doi.org/10.3969/j.issn.1673-5374.2013.21.009CrossRefPubMedPubMedCentral

68.

Sardão, V. A., Oliveira, P. J., Holy, J., Oliveira, C. R., & Wallace, K. B. (2009). Doxorubicin-induced mitochondrial dysfunction is secondary to nuclear p53 activation in H9c2 cardiomyoblasts. Cancer Chemotherapy and Pharmacology, 64, 811–827. https://doi.org/10.1007/s00280-009-0932-xCrossRefPubMed

69.

Ma, Q. (2013). Role of nrf2 in oxidative stress and toxicity. Annual Review of Pharmacology and Toxicology, 53, 401–426. https://doi.org/10.1146/annurev-pharmtox-011112-140320CrossRefPubMedPubMedCentral

70.

Loboda, A., Damulewicz, M., Pyza, E., Jozkowicz, A., & Dulak, J. (2016). Role of Nrf2/HO-1 system in development, oxidative stress response and diseases: An evolutionarily conserved mechanism. Cellular and Molecular Life Sciences: CMLS, 73, 3221–3247. https://doi.org/10.1007/s00018-016-2223-0CrossRefPubMed

71.

Singh, P., Sharma, R., McElhanon, K., Allen, C. D., Megyesi, J. K., Beneš, H., & Singh, S. P. (2015). Sulforaphane protects the heart from doxorubicin-induced toxicity. Free Radical Biology & Medicine, 86, 90–101. https://doi.org/10.1016/j.freeradbiomed.2015.05.028CrossRef

72.

Chen, M., Samuel, V. P., Wu, Y., Dang, M., Lin, Y., Sriramaneni, R., Sah, S. K., Chinnaboina, G. K., & Zhang, G. (2019). Nrf2/HO-1 mediated protective activity of genistein against doxorubicin-induced cardiac toxicity. Journal of Environmental Pathology, Toxicology and Oncology, 38, 143–152. https://doi.org/10.1615/JEnvironPatholToxicolOncol.2019029341CrossRefPubMed

73.

Cheng, X., Liu, D., Xing, R., Song, H., Tian, X., Yan, C., & Han, Y. (2020). Orosomucoid 1 attenuates doxorubicin-induced oxidative stress and apoptosis in cardiomyocytes via Nrf2 signaling. BioMed Research International, 2020, 5923572. https://doi.org/10.1155/2020/5923572CrossRefPubMedPubMedCentral

74.

El-Agamy, D. S., El-Harbi, K. M., Khoshhal, S., Ahmed, N., Elkablawy, M. A., Shaaban, A. A., & Abo-Haded, H. M. (2019). Pristimerin protects against doxorubicin-induced cardiotoxicity and fibrosis through modulation of Nrf2 and MAPK/NF-kB signaling pathways. Cancer Management and Research, 11, 47–61. https://doi.org/10.2147/cmar.s186696CrossRefPubMed

75.

Fadillioglu, E., Oztas, E., Erdogan, H., Yagmurca, M., Sogut, S., Ucar, M., & Irmak, M. K. (2004). Protective effects of caffeic acid phenethyl ester on doxorubicin-induced cardiotoxicity in rats. Journal of Applied Toxicology: An International Journal, 24, 47–52.

76.

Alkreathy, H., Damanhouri, Z. A., Ahmed, N., Slevin, M., Ali, S. S., & Osman, A.-M.M. (2010). Aged garlic extract protects against doxorubicin-induced cardiotoxicity in rats. Food and Chemical Toxicology, 48, 951–956.PubMed

77.

Sheibani, M., Faghir-Ghanesefat, H., Dehpour, S., Keshavarz-Bahaghighat, H., Sepand, M. R., Ghahremani, M. H., Azizi, Y., Rahimi, N., & Dehpour, A. R. (2019). Sumatriptan protects against myocardial ischaemia-reperfusion injury by inhibition of inflammation in rat model. Inflammopharmacology, 27, 1071–1080. https://doi.org/10.1007/s10787-019-00586-5CrossRefPubMed

78.

Bazmandegan, G., Amirteimoury, M., Kaeidi, A., Shamsizadeh, A., Khademalhosseini, M., Nematollahi, M. H., Hassanipour, M., & Fatemi, I. (2019). Sumatriptan ameliorates renal injury induced by cisplatin in mice. Iranian Journal of Basic Medical Sciences, 22, 563–567. https://doi.org/10.22038/ijbms.2019.33620.8020CrossRefPubMedPubMedCentral

79.

Eslami, F., Rahimi, N., Ostovaneh, A., Ghasemi, M., Dejban, P., Abbasi, A., & Dehpour, A. R. (2021). Sumatriptan reduces severity of status epilepticus induced by lithium-pilocarpine through nitrergic transmission and 5-HT(1B/D) receptors in rats: A pharmacological-based evidence. Fundamental & Clinical Pharmacology, 35, 131–140. https://doi.org/10.1111/fcp.12590CrossRef

80.

Mohammad, S., Hedyeh, F.-G., Yaser, A., Tahmineh, M., Hasan, Y. M., Roya Sattarzadeh, B., Amir Hossein, E., & Ahmad Reza, D. (2021). Anti-inflammatory and antioxidative effects of sumatriptan against doxorubicin-induced cardiotoxicity in rat. Acta Medica Iranica. https://doi.org/10.18502/acta.v59i7.7020CrossRef

81.

Iqbal, M., Dubey, K., Anwer, T., Ashish, A., & Pillai, K. K. (2008). Protective effects of telmisartan against acute doxorubicin-induced cardiotoxicity in rats. Pharmacological Reports, 60, 382.PubMed

82.

Siveski-Iliskovic, N., Hill, M., Chow, D. A., & Singal, P. K. (1995). Probucol protects against adriamycin cardiomyopathy without interfering with its antitumor effect. Circulation, 91, 10–15. https://doi.org/10.1161/01.cir.91.1.10CrossRefPubMed

83.

Siveski-Iliskovic, N., Kaul, N., & Singal, P. K. (1994). Probucol promotes endogenous antioxidants and provides protection against adriamycin-induced cardiomyopathy in rats. Circulation, 89, 2829–2835. https://doi.org/10.1161/01.cir.89.6.2829CrossRefPubMed

84.

Nagi, M. N., & Mansour, M. A. (2000). Protective effect of thymoquinone against doxorubicin-induced cardiotoxicity in rats: A possible mechanism of protection. Pharmacological Research, 41, 283–289.PubMed

85.

Sadzuka, Y., Sugiyama, T., Shimoi, K., Kinae, N., & Hirota, S. (1997). Protective effect of flavonoids on doxorubicin-induced cardiotoxicity. Toxicology letters, 92, 1–7.PubMed

86.

Zhang, Y., Ma, C., Liu, C., & Wei, F. (2020). Luteolin attenuates doxorubicin-induced cardiotoxicity by modulating the PHLPP1/AKT/Bcl-2 signalling pathway. PeerJ, 8, e8845.PubMedPubMedCentral

87.

Chen, J.-Y., Hu, R.-Y., & Chou, H.-C. (2013). Quercetin-induced cardioprotection against doxorubicin cytotoxicity. Journal of Biomedical Science, 20, 1–11.PubMedPubMedCentral

88.

Kaiserová, H., Šimůnek, T., van der Vijgh, W. J., Bast, A., & Kvasničková, E. (2007). Flavonoids as protectors against doxorubicin cardiotoxicity: Role of iron chelation, antioxidant activity and inhibition of carbonyl reductase. Biochimica et Biophysica Acta (BBA)-Molecular Basis of Disease, 1772, 1065–1074.

89.

Laughton, M. J., Halliwell, B., Evans, P. J., Robin, J., & Hoult, S. (1989). Antioxidant and pro-oxidant actions of the plant phenolics quercetin, gossypol and myricetin: Effects on lipid peroxidation, hydroxyl radical generation and bleomycin-dependent damage to DNA. Biochemical Pharmacology, 38, 2859–2865.PubMed

90.

Chang, D., Li, H., Qian, C., & Wang, Y. (2019). Diohf protects against doxorubicin-induced cardiotoxicity through ERK1 signaling pathway. Frontiers in Pharmacology, 10, 1081.PubMedPubMedCentral

91.

Wang, H., Yu, P., Gou, H., Zhang, J., Zhu, M., Wang, Z. H., Tian, J. W., Jiang, Y. T., & Fu, F. H. (2012). Cardioprotective effects of 20(S)-ginsenoside Rh2 against doxorubicin-induced cardiotoxicity in vitro and in vivo. Evidence-Based Complementary and Alternative Medicine, 2012, 506214. https://doi.org/10.1155/2012/506214CrossRefPubMedPubMedCentral

92.

Li, L., Pan, Q., Han, W., Liu, Z., Li, L., & Hu, X. (2007). Schisandrin B prevents doxorubicin-induced cardiotoxicity via enhancing glutathione redox cycling. Clinical Cancer Research, 13, 6753–6760. https://doi.org/10.1158/1078-0432.Ccr-07-1579CrossRefPubMed

93.

Zhu, W., Soonpaa, M. H., Chen, H., Shen, W., Payne, R. M., Liechty, E. A., Caldwell, R. L., Shou, W., & Field, L. J. (2009). Acute doxorubicin cardiotoxicity is associated with p53-induced inhibition of the mammalian target of rapamycin pathway. Circulation, 119, 99–106. https://doi.org/10.1161/CIRCULATIONAHA.108.799700CrossRefPubMed

94.

Timm, K. N., & Tyler, D. J. (2020). The role of AMPK activation for cardioprotection in doxorubicin-induced cardiotoxicity. Cardiovascular Drugs and Therapy, 34, 255–269. https://doi.org/10.1007/s10557-020-06941-xCrossRefPubMedPubMedCentral

95.

Kobashigawa, L. C., Xu, Y. C., Padbury, J. F., Tseng, Y.-T., & Yano, N. (2014). Metformin protects cardiomyocyte from doxorubicin induced cytotoxicity through an AMP-activated protein kinase dependent signaling pathway: an in vitro study. PLoS ONE, 9, e104888.PubMedPubMedCentral

96.

Zilinyi, R., Czompa, A., Czegledi, A., Gajtko, A., Pituk, D., Lekli, I., & Tosaki, A. (2018). The cardioprotective effect of metformin in doxorubicin-induced cardiotoxicity: The role of autophagy. Molecules (Basel, Switzerland). https://doi.org/10.3390/molecules23051184CrossRef

97.

Huelsenbeck, J., Henninger, C., Schad, A., Lackner, K. J., Kaina, B., & Fritz, G. (2011). Inhibition of Rac1 signaling by lovastatin protects against anthracycline-induced cardiac toxicity. Cell Death & Disease, 2, e190. https://doi.org/10.1038/cddis.2011.65CrossRef

98.

Rawat, P. S., Jaiswal, A., Khurana, A., Bhatti, J. S., & Navik, U. (2021). Doxorubicin-induced cardiotoxicity: An update on the molecular mechanism and novel therapeutic strategies for effective management. Biomedicine & Pharmacotherapy, 139, 111708. https://doi.org/10.1016/j.biopha.2021.111708CrossRef

99.

Vedam, K., Nishijima, Y., Druhan, L. J., Khan, M., Moldovan, N. I., Zweier, J. L., & Ilangovan, G. (2010). Role of heat shock factor-1 activation in the doxorubicin-induced heart failure in mice. American Journal of Physiology, Heart and Circulatory Physiology, 298, H1832–H1841. https://doi.org/10.1152/ajpheart.01047.2009CrossRefPubMed

100.

Liu, P., Bao, H. Y., Jin, C. C., Zhou, J. C., Hua, F., Li, K., Lv, X. X., Cui, B., Hu, Z. W., & Zhang, X. W. (2019). Targeting extracellular heat shock protein 70 ameliorates doxorubicin-induced heart failure through resolution of toll-like receptor 2-mediated myocardial inflammation. Journal of the American Heart Association, 8, e012338. https://doi.org/10.1161/jaha.119.012338CrossRefPubMedPubMedCentral

101.

Shan, Y. X., Liu, T. J., Su, H. F., Samsamshariat, A., Mestril, R., & Wang, P. H. (2003). Hsp10 and Hsp60 modulate Bcl-2 family and mitochondria apoptosis signaling induced by doxorubicin in cardiac muscle cells. Journal of Molecular and Cellular Cardiology, 35, 1135–1143. https://doi.org/10.1016/s0022-2828(03)00229-3CrossRefPubMed

102.

Zhao, D., Xue, C., Li, J., Feng, K., Zeng, P., Chen, Y., Duan, Y., Zhang, S., Li, X., & Han, J. (2020). Adiponectin agonist ADP355 ameliorates doxorubicin-induced cardiotoxicity by decreasing cardiomyocyte apoptosis and oxidative stress. Biochemical and Biophysical Research Communications, 533, 304–312.PubMed

103.

Ramond, A., Sartorius, E., Mousseau, M., Ribuot, C., & Joyeux-Faure, M. (2008). Erythropoietin pretreatment protects against acute chemotherapy toxicity in isolated rat hearts. Experimental Biology and Medicine, 233, 76–83. https://doi.org/10.3181/0706-RM-152CrossRefPubMed

104.

Man, S. M., Karki, R., Briard, B., Burton, A., Gingras, S., Pelletier, S., & Kanneganti, T.-D. (2017). Differential roles of caspase-1 and caspase-11 in infection and inflammation. Scientific Reports, 7, 45126. https://doi.org/10.1038/srep45126CrossRefPubMed

105.

Yu, W., Qin, X., Zhang, Y., Qiu, P., Wang, L., Zha, W., & Ren, J. (2020). Curcumin suppresses doxorubicin-induced cardiomyocyte pyroptosis via a PI3K/Akt/mTOR-dependent manner. Cardiovascular Diagnosis and Therapy, 10, 752–769. https://doi.org/10.21037/cdt-19-707CrossRefPubMedPubMedCentral

106.

Chen, Y. L., Chung, S. Y., Chai, H. T., Chen, C. H., Liu, C. F., Chen, Y. L., Huang, T. H., Zhen, Y. Y., Sung, P. H., Sun, C. K., Chua, S., Lu, H. I., Lee, F. Y., Sheu, J. J., & Yip, H. K. (2015). Early administration of carvedilol protected against doxorubicin-induced cardiomyopathy. The Journal of Pharmacology and Experimental Therapeutics, 355, 516–527. https://doi.org/10.1124/jpet.115.225375CrossRefPubMed

107.

Dulhunty, A., & Casarotto, B. (2011). The ryanodine receptor: A pivotal Ca²⁺ regulatory protein and potential therapeutic drug target. Current Drug Targets, 12, 709–723.PubMed

108.

Dewenter, M., von der Lieth, A., Katus, H. A., & Backs, J. (2017). Calcium signaling and transcriptional regulation in cardiomyocytes. Circulation Research, 121, 1000–1020.PubMed

109.

Aziz, A. U. R., Geng, C., Li, W., Yu, X., Qin, K.-R., Wang, H., & Liu, B. (2019). Doxorubicin induces ER calcium release via Src in rat ovarian follicles. Toxicological Sciences, 168, 171–178.PubMed

110.

Octavia, Y., Tocchetti, C. G., Gabrielson, K. L., Janssens, S., Crijns, H. J., & Moens, A. L. (2012). Doxorubicin-induced cardiomyopathy: From molecular mechanisms to therapeutic strategies. Journal of Molecular and Cellular Cardiology, 52, 1213–1225.PubMed

111.

Yarmohmmadi, F., Rahimi, N., Faghir-Ghanesefat, H., Javadian, N., Abdollahi, A., Pasalar, P., Jazayeri, F., Ejtemaeemehr, S., & Dehpour, A. R. (2017). Protective effects of agmatine on doxorubicin-induced chronic cardiotoxicity in rat. European Journal of Pharmacology, 796, 39–44.PubMed

112.

Khalilzadeh, M., Abdollahi, A., Abdolahi, F., Abdolghaffari, A. H., Dehpour, A. R., & Jazaeri, F. (2018). Protective effects of magnesium sulfate against doxorubicin induced cardiotoxicity in rats. Life Sciences, 207, 436–441.PubMed

113.

Gross, R. A., Moises, H. C., Uhler, M. D., & Macdonald, R. L. (1990). Dynorphin A and cAMP-dependent protein kinase independently regulate neuronal calcium currents. Proceedings of the National Academy of Sciences, 87, 7025–7029.

114.

North, R. A., Williams, J. T., Surprenant, A., & Christie, M. J. (1987). Mu and delta receptors belong to a family of receptors that are coupled to potassium channels. Proceedings of the National Academy of Sciences, 84, 5487–5491.

115.

Lashgari, N. A., Roudsari, N. M., Zandi, N., Pazoki, B., Rezaei, A., Hashemi, M., Momtaz, S., Rahimi, R., Shayan, M., Dehpour, A. R., & Abdolghaffari, A. H. (2021). Current overview of opioids in progression of inflammatory bowel disease; pharmacological and clinical considerations. Molecular Biology Reports, 48, 855–874. https://doi.org/10.1007/s11033-020-06095-xCrossRefPubMed

116.

Zamanian, G., Shayan, M., Rahimi, N., Bahremand, T., Shafaroodi, H., Ejtemaei-Mehr, S., Aghaei, I., & Dehpour, A. R. (2020). Interaction of morphine tolerance with pentylenetetrazole-induced seizure threshold in mice: The role of NMDA-receptor/NO pathway. Epilepsy & Behavior, 112, 107343. https://doi.org/10.1016/j.yebeh.2020.107343CrossRef

117.

Kelishomi, R. B., Ejtemaeemehr, S., Tavangar, S. M., Rahimian, R., Mobarakeh, J. I., & Dehpour, A. R. (2008). Morphine is protective against doxorubicin-induced cardiotoxicity in rat. Toxicology, 243, 96–104.PubMed

118.

Goodenough, D. A., & Paul, D. L. (2009). Gap junctions. Cold Spring Harbor Perspectives in Biology, 1, a002576.PubMedPubMedCentral

119.

Severs, N. J. (1994). Pathophysiology of gap junctions in heart disease. Journal of Cardiovascular Electrophysiology, 5, 462–475.PubMed

120.

Siti, H. N., Jalil, J., Asmadi, A. Y., & Kamisah, Y. (2020). Effects of quercetin on cardiac function in pressure overload and postischemic cardiac injury in rodents: A systematic review and meta-analysis. Cardiovascular Drugs and Therapy, 16, 1–15.

121.

Srisakuldee, W., Makazan, Z., Nickel, B. E., Zhang, F., Thliveris, J. A., Pasumarthi, K. B., & Kardami, E. (2014). The FGF-2-triggered protection of cardiac subsarcolemmal mitochondria from calcium overload is mitochondrial connexin 43-dependent. Cardiovascular Research, 103, 72–80.PubMed

122.

Pecoraro, M., Ciccarelli, M., Fiordelisi, A., Iaccarino, G., Pinto, A., & Popolo, A. (2018). Diazoxide improves mitochondrial connexin 43 expression in a mouse model of doxorubicin-induced cardiotoxicity. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms19030757CrossRefPubMedPubMedCentral

123.

Elhadidy, M. G., Elmasry, A., Rabei, M. R., & Eladel, A. E. (2020). Effect of ghrelin on VEGF-B and connexin-43 in a rat model of doxorubicin-induced cardiomyopathy. Journal of Basic and Clinical Physiology and Pharmacology. https://doi.org/10.1515/jbcpp-2018-0212CrossRefPubMed

124.

Zhang, H., Zhang, A., Guo, C., Shi, C., Zhang, Y., Liu, Q., Sparatore, A., & Wang, C. (2011). S-diclofenac protects against doxorubicin-induced cardiomyopathy in mice via ameliorating cardiac gap junction remodeling. PLoS ONE, 6, e26441.PubMedPubMedCentral

125.

Michan, S., & Sinclair, D. (2007). Sirtuins in mammals: Insights into their biological function. Biochemical Journal, 404, 1–13.

126.

Tomaselli, D., Steegborn, C., Mai, A., & Rotili, D. (2020). Sirt4: A multifaceted enzyme at the crossroads of mitochondrial metabolism and cancer. Frontiers in Oncology, 10, 474.PubMedPubMedCentral

127.

Dolinsky, V. W. (2017). The role of sirtuins in mitochondrial function and doxorubicin-induced cardiac dysfunction. Biological Chemistry, 398, 955–974.PubMed

128.

Cheung, K. G., Cole, L. K., Xiang, B., Chen, K., Ma, X., Myal, Y., Hatch, G. M., Tong, Q., & Dolinsky, V. W. (2015). Sirtuin-3 (SIRT3) protein attenuates doxorubicin-induced oxidative stress and improves mitochondrial respiration in H9c2 cardiomyocytes. Journal of Biological Chemistry, 290, 10981–10993.

129.

Liu, M. H., Shan, J., Li, J., Zhang, Y., & Lin, X. L. (2016). Resveratrol inhibits doxorubicin-induced cardiotoxicity via sirtuin 1 activation in H9c2 cardiomyocytes. Experimental and Therapeutic Medicine, 12, 1113–1118.PubMedPubMedCentral

130.

Ruan, Y., Dong, C., Patel, J., Duan, C., Wang, X., Wu, X., Cao, Y., Pu, L., Lu, D., & Shen, T. (2015). SIRT1 suppresses doxorubicin-induced cardiotoxicity by regulating the oxidative stress and p38MAPK pathways. Cellular Physiology and Biochemistry, 35, 1116–1124.PubMed

131.

Pillai, V. B., Kanwal, A., Fang, Y. H., Sharp, W. W., Samant, S., Arbiser, J., & Gupta, M. P. (2017). Honokiol, an activator of Sirtuin-3 (SIRT3) preserves mitochondria and protects the heart from doxorubicin-induced cardiomyopathy in mice. Oncotarget, 8, 34082.PubMedPubMedCentral

132.

Needham, D. M., Shufelt, K. A., Tomlinson, G., Scholey, J. W., & Newton, G. E. (2004). Troponin I and T levels in renal failure patients without acute coronary syndrome: A systematic review of the literature. The Canadian Journal of Cardiology, 20, 1212–1218.PubMed

133.

Jin, J.-P. (2016). Evolution, regulation, and function of N-terminal variable region of troponin T: Modulation of muscle contractility and beyond. International Review of Cell and Molecular Biology, 321, 1–28.PubMed

134.

Bleuel, H., Deschl, U., Bertsch, T., Bölz, G., & Rebel, W. (1995). Diagnostic efficiency of troponin T measurements in rats with experimental myocardial cell damage. Experimental and Toxicologic Pathology, 47, 121–127.PubMed

135.

Mair, J., & Apple, F. (1997). Progress in myocardial damage detection: New biochemical markers for clinicians. Critical Reviews in Clinical Laboratory Sciences, 34, 1–66.PubMed

136.

Rahimi Balaei, M., Momeny, M., Babaeikelishomi, R., Ejtemaei Mehr, S., Tavangar, S. M., & Dehpour, A. R. (2010). The modulatory effect of lithium on doxorubicin-induced cardiotoxicity in rat. European Journal of Pharmacology, 641, 193–198. https://doi.org/10.1016/j.ejphar.2010.05.046CrossRefPubMed

137.

Chang, E. A., Jin, S. W., Nam, M. H., & Kim, S. D. (2019). Human induced pluripotent stem cells: Clinical significance and applications in neurologic diseases. Journal of Korean Neurosurgical Society, 62, 493–501. https://doi.org/10.3340/jkns.2018.0222CrossRefPubMedPubMedCentral

138.

Matsui, T., Miyamoto, N., Saito, F., & Shinozawa, T. (2020). Molecular profiling of human induced pluripotent stem cell-derived cells and their application for drug safety study. Current Pharmaceutical Biotechnology, 21, 807–828. https://doi.org/10.2174/1389201021666200422090952CrossRefPubMed

139.

Devalla, H. D., & Passier, R. (2018). Cardiac differentiation of pluripotent stem cells and implications for modeling the heart in health and disease. Science Translational Medicine. https://doi.org/10.1126/scitranslmed.aah5457CrossRefPubMed

140.

Blinova, K., Dang, Q., Millard, D., Smith, G., Pierson, J., Guo, L., Brock, M., Lu, H. R., Kraushaar, U., Zeng, H., Shi, H., Zhang, X., Sawada, K., Osada, T., Kanda, Y., Sekino, Y., Pang, L., Feaster, T. K., Kettenhofen, R., … Gintant, G. (2018). International multisite study of human-induced pluripotent stem cell-derived cardiomyocytes for drug proarrhythmic potential assessment. Cell Reports, 24, 3582–3592. https://doi.org/10.1016/j.celrep.2018.08.079CrossRefPubMed

141.

Schwach, V., Slaats, R. H., & Passier, R. (2020). Human pluripotent stem cell-derived cardiomyocytes for assessment of anticancer drug-induced cardiotoxicity. Frontiers in Cardiovascular Medicine. https://doi.org/10.3389/fcvm.2020.00050CrossRefPubMedPubMedCentral

142.

Maillet, A., Tan, K., Chai, X., Sadananda, S. N., Mehta, A., Ooi, J., Hayden, M. R., Pouladi, M. A., Ghosh, S., Shim, W., & Brunham, L. R. (2016). Modeling doxorubicin-induced cardiotoxicity in human pluripotent stem cell derived-cardiomyocytes. Science and Reports, 6, 25333. https://doi.org/10.1038/srep25333CrossRef

143.

Burridge, P. W., Li, Y. F., Matsa, E., Wu, H., Ong, S. G., Sharma, A., Holmström, A., Chang, A. C., Coronado, M. J., Ebert, A. D., Knowles, J. W., Telli, M. L., Witteles, R. M., Blau, H. M., Bernstein, D., Altman, R. B., & Wu, J. C. (2016). Human induced pluripotent stem cell-derived cardiomyocytes recapitulate the predilection of breast cancer patients to doxorubicin-induced cardiotoxicity. Nature Medicine, 22, 547–556. https://doi.org/10.1038/nm.4087CrossRefPubMedPubMedCentral

144.

Cui, N., Wu, F., Lu, W. J., Bai, R., Ke, B., Liu, T., Li, L., Lan, F., & Cui, M. (2019). Doxorubicin-induced cardiotoxicity is maturation dependent due to the shift from topoisomerase IIα to IIβ in human stem cell derived cardiomyocytes. Journal of Cellular and Molecular Medicine, 23, 4627–4639. https://doi.org/10.1111/jcmm.14346CrossRefPubMedPubMedCentral

145.

Zhao, L., & Zhang, B. (2017). Doxorubicin induces cardiotoxicity through upregulation of death receptors mediated apoptosis in cardiomyocytes. Science and Reports, 7, 44735. https://doi.org/10.1038/srep44735CrossRef

146.

McSweeney, K. M., Bozza, W. P., Alterovitz, W.-L., & Zhang, B. (2019). Transcriptomic profiling reveals p53 as a key regulator of doxorubicin-induced cardiotoxicity. Cell Death Discovery, 5, 102. https://doi.org/10.1038/s41420-019-0182-6CrossRefPubMedPubMedCentral

147.

Li, J., Wang, P. Y., Long, N. A., Zhuang, J., Springer, D. A., Zou, J., Lin, Y., Bleck, C. K. E., Park, J. H., Kang, J. G., & Hwang, P. M. (2019). p53 prevents doxorubicin cardiotoxicity independently of its prototypical tumor suppressor activities. Proceedings of the National Academy of Sciences of the United States of America, 116, 19626–19634. https://doi.org/10.1073/pnas.1904979116CrossRefPubMedPubMedCentral

148.

Deng, S., Yan, T., Jendrny, C., Nemecek, A., Vincetic, M., Gödtel-Armbrust, U., & Wojnowski, L. (2014). Dexrazoxane may prevent doxorubicin-induced DNA damage via depleting both Topoisomerase II isoforms. BMC Cancer, 14, 842. https://doi.org/10.1186/1471-2407-14-842CrossRefPubMedPubMedCentral

149.

Ahmed, R. E., Anzai, T., Chanthra, N., & Uosaki, H. (2020). A brief review of current maturation methods for human induced pluripotent stem cells-derived cardiomyocytes. Frontiers in Cell and Developmental Biology. https://doi.org/10.3389/fcell.2020.00178CrossRefPubMedPubMedCentral

150.

Pang, L. (2020). Toxicity testing in the era of induced pluripotent stem cells: A perspective regarding the use of patient-specific induced pluripotent stem cell–derived cardiomyocytes for cardiac safety evaluation. Current Opinion in Toxicology, 23–24, 50–55. https://doi.org/10.1016/j.cotox.2020.04.001CrossRef

151.

Soma, Y., Morita, Y., Kishino, Y., Kanazawa, H., Fukuda, K., & Tohyama, S. (2021). The present state and future perspectives of cardiac regenerative therapy using human pluripotent stem cells. Frontiers in Cardiovascular Medicine. https://doi.org/10.3389/fcvm.2021.774389CrossRefPubMedPubMedCentral

Titel: Doxorubicin-Induced Cardiotoxicity: An Overview on Pre-clinical Therapeutic Approaches
verfasst von: Mohammad Sheibani
Yaser Azizi
Maryam Shayan
Sadaf Nezamoleslami
Faezeh Eslami
Mohammad Hadi Farjoo
Ahmad Reza Dehpour
Publikationsdatum: 21.01.2022
Verlag: Springer US
Schlagwort: Heart Failure
Erschienen in: Cardiovascular Toxicology / Ausgabe 4/2022
Print ISSN: 1530-7905
Elektronische ISSN: 1559-0259
DOI: https://doi.org/10.1007/s12012-022-09721-1

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

Doxorubicin-Induced Cardiotoxicity: An Overview on Pre-clinical Therapeutic Approaches

Abstract

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 4/2022

Indoxyl Sulfate Activates NLRP3 Inflammasome to Induce Cardiac Contractile Dysfunction Accompanied by Myocardial Fibrosis and Hypertrophy

Targeting PPARs Signaling Pathways in Cardiotoxicity by Natural Compounds

Circ-SWT1 Ameliorates H2O2-Induced Apoptosis, Oxidative Stress and Endoplasmic Reticulum Stress in Cardiomyocytes via miR-192-5p/SOD2 Axis

Effects of Low- and High-Dose Valproic Acid and Lamotrigine on the Heart in Female Rats

LncRNA HOTTIP Knockdown Attenuates Acute Myocardial Infarction via Regulating miR-92a-2/c-Met Axis

Rosuvastatin Alleviates Coronary Microembolization-Induced Cardiac Injury by Suppressing Nox2-Induced ROS Overproduction and Myocardial Apoptosis